MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  2017-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.leukres.2017.05.015PMID 28544907
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib

  2016cited by this paper
• The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review).

  2016cited by this paper
• MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia

  2016cited by this paper
• PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs)

  2015cited by this paper
• Treatment milestones in chronic myelogenous leukemia: stay the course or change therapy?

  2015cited by this paper
• BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer

  2015cited by this paper
• Identification of New microRNA Biomarkers and Candidate Target Genes in Primitive CML Cells Using Global Comparative RNA analyses

  2014cited by this paper
• Do Post Discharge Phone Calls Improve Care Transitions? A Cluster-Randomized Trial

  2014cited by this paper
• Identifying and Validating a Combined mRNA and MicroRNA Signature in Response to Imatinib Treatment in a Chronic Myeloid Leukemia Cell Line

  2014cited by this paper
• 5′ isomiR variation is of functional and evolutionary importance

  2014cited by this paper
• Management of imatinib-resistant patients with chronic myeloid leukemia

  2013cited by this paper
• Low Expression of miR-196b Enhances the Expression of BCR-ABL1 and HOXA9 Oncogenes in Chronic Myeloid Leukemogenesis

  2013cited by this paper
• Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma

  2013cited by this paper
• Rfam 11.0: 10 years of RNA families

  2012cited by this paper
• Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists

  2012cited by this paper
• IsomiRs--the overlooked repertoire in the dynamic microRNAome.

  2012cited by this paper
• DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways

  2012cited by this paper
• Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients

  2012cited by this paper
• Downregulation of Mir-31, Mir-155, and Mir-564 in Chronic Myeloid Leukemia Cells

  2012cited by this paper
• BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

  2011cited by this paper
• Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy

  2011cited by this paper
• Expression patterns of microRNAs associated with CML phases and their disease related targets

  2011cited by this paper
• Hereditary breast and ovarian cancer: new genes, new treatments, new concepts.

  2011cited by this paper
• Mutation of the RAD51C gene in a Fanconi anemia–like disorder

  2010cited by this paper
• Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia

  2010cited by this paper
• Next Generation Sequencing of miRNAs – Strategies, Resources and Methods

  2010cited by this paper
• UAF1 Is a Subunit of Multiple Deubiquitinating Enzyme Complexes*

  2009cited by this paper
• ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function.

  2009cited by this paper
• MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

  2009cited by this paper
• How the fanconi anemia pathway guards the genome.

  2009cited by this paper
• Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis.

  2009cited by this paper
• Searching for SNPs with cloud computing

  2009cited by this paper
• Ultrafast and memory-efficient alignment of short DNA sequences to the human genome

  2009cited by this paper
• GtRNAdb: a database of transfer RNA genes detected in genomic sequence

  2008cited by this paper
• Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.

  2008cited by this paper
• Mapping and quantifying mammalian transcriptomes by RNA-Seq

  2008cited by this paper
• Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression.

  2008cited by this paper
• A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway.

  2007cited by this paper
• Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.

  2007cited by this paper
• Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

  2005cited by this paper
• Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

  2004cited by this paper
• Impaired Type I IFN-Induced Jak/STAT Signaling in FA-C Cells and Abnormal CD4+ Th Cell Subsets in Fancc−/− Mice1

  2004cited by this paper
• Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

  2003cited by this paper
• Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.

  2003cited by this paper
• Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis

  2002cited by this paper
• BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability

  2002cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells.

  2001cited by this paper
• ATR and ATRIP: Partners in Checkpoint Signaling

  2001cited by this paper
• KEGG: Kyoto Encyclopedia of Genes and Genomes

  2000cited by this paper
• A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.

  2000cited by this paper
• KEGG: Kyoto Encyclopedia of Genes and Genomes

  1999cited by this paper
• CHRONIC MYELOID LEUKEMIA: AFTER A DECADE OF IMATINIB _________________________________________________________

  year unknowncited by this paper

• Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia

  2025cites this paper
• MicroRNA-99 family in cancer: molecular mechanisms for clinical applications

  2025cites this paper
• Investigation of TSRP reverses imatinib resistance through the PI3K / Akt pathway in chronic myeloid leukemia

  2024cites this paper
• Correlation analysis of bone marrow microvessel density and miRNA expression on drug resistance in patients with chronic myelogenous leukemia after tyrosine kinase inhibitor treatment

  2024cites this paper
• The role of mir-151a-5p in tumorigenesis; A systematic review.

  2023cites this paper
• MiRNA-146a—A Key Player in Immunity and Diseases

  2023cites this paper
• Prevalence of anemia among chronic myeloid leukemia patients treated with Imatinib: A evidence based meta-analysis.

  2022cites this paper
• HucMSC exosomes promoted imatinib-induced apoptosis in K562-R cells via a miR-145a-5p/USP6/GLS1 axis

  2022cites this paper
• CircRNAs: biogenesis, functions, and role in drug-resistant Tumours

  2020cites this paper
• A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance

  2020cites this paper
• MicroRNAs and response to therapy in leukemia

  2019cites this paper
• miR‐146a‐5p: Expression, regulation, and functions in cancer

  2019cites this paper
• miR-146a-5p targets TCSF and influences cell growth and apoptosis to repress NSCLC progression

  2019cites this paper
• Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia

  2018cites this paper